APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Pertuzumab

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Pertuzumab Market Outlook and Growth Opportunities 2026

Report ID 174024010426 December 2025198 pages

Choose your research edition.

Industry ResearchPertuzumab Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Pertuzumab Industry Growth and Trends Forecast to 203299 pages · $3,450 USDMarket StructureGlobal Pertuzumab Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032181 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pertuzumab Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Pertuzumab Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Pertuzumab market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Pertuzumab is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Pertuzumab is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Pertuzumab is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Pertuzumab market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Pertuzumab market include Abnova Corporation, Biocon Limited, Bio-Techne, Celltrion, InvivoGen, Pfizer and Novartis AG, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Pertuzumab market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Pertuzumab and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Pertuzumab sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Pertuzumab market size, projected growth trends, production technologies, key applications, and end-use industries.

Pertuzumab Segment by Company

Abnova Corporation

Biocon Limited

Bio-Techne

Celltrion

InvivoGen

Pfizer

Novartis AG

Pertuzumab Segment by Type

Human Source

Animal Source

Pertuzumab Segment by Application

Hospital

Medical Center

Pertuzumab Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Pertuzumab status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Pertuzumab market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Pertuzumab significant trends, drivers, influence factors in global and regions.

6. To analyze Pertuzumab competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pertuzumab market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pertuzumab and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pertuzumab.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Pertuzumab market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Pertuzumab industry.

Chapter 3: Detailed analysis of Pertuzumab manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Pertuzumab in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Pertuzumab in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Pertuzumab Industry Trends Table 2. Pertuzumab Industry Drivers Table 3. Pertuzumab Industry Opportunities and Challenges Table 4. Pertuzumab Industry Restraints Table 5. Global Pertuzumab Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Pertuzumab Revenue Share by Company (2021-2026) Table 7. Global Pertuzumab Sales Volume by Company (Tons) & (2021-2026) Table 8. Global Pertuzumab Sales Volume Share by Company (2021-2026) Table 9. Global Pertuzumab Average Price (US$/Ton) of Company (2021-2026) Table 10. Global Pertuzumab Company Ranking, (2024-2026) & (USD Million) Table 11. Global Pertuzumab Key Company Manufacturing Base & Headquarters Table 12. Global Pertuzumab Company, Product Type & Application Table 13. Global Pertuzumab Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Pertuzumab by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Human Source Table 18. Significant Companies of Animal Source Table 19. Global Pertuzumab Sales Volume by Type 2021 VS 2025 VS 2032 (Tons) Table 20. Global Pertuzumab Sales Volume by Type (2021-2026) & (Tons) Table 21. Global Pertuzumab Sales Volume by Type (2027-2032) & (Tons) Table 22. Global Pertuzumab Sales Volume Share by Type (2021-2026) Table 23. Global Pertuzumab Sales Volume Share by Type (2027-2032) Table 24. Global Pertuzumab Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Pertuzumab Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Pertuzumab Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Pertuzumab Sales Value Share by Type (2021-2026) Table 28. Global Pertuzumab Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospital Table 30. Significant Companies of Medical Center Table 31. Global Pertuzumab Sales Volume by Application 2021 VS 2025 VS 2032 (Tons) Table 32. Global Pertuzumab Sales Volume by Application (2021-2026) & (Tons) Table 33. Global Pertuzumab Sales Volume by Application (2027-2032) & (Tons) Table 34. Global Pertuzumab Sales Volume Share by Application (2021-2026) Table 35. Global Pertuzumab Sales Volume Share by Application (2027-2032) Table 36. Global Pertuzumab Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Pertuzumab Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global Pertuzumab Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global Pertuzumab Sales Value Share by Application (2021-2026) Table 40. Global Pertuzumab Sales Value Share by Application (2027-2032) Table 41. Global Pertuzumab Sales by Region: 2021 VS 2025 VS 2032 (Tons) Table 42. Global Pertuzumab Sales by Region (2021-2026) & (Tons) Table 43. Global Pertuzumab Sales Market Share by Region (2021-2026) Table 44. Global Pertuzumab Sales by Region (2027-2032) & (Tons) Table 45. Global Pertuzumab Sales Market Share by Region (2027-2032) Table 46. Global Pertuzumab Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Pertuzumab Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global Pertuzumab Sales Value Share by Region (2021-2026) Table 49. Global Pertuzumab Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global Pertuzumab Sales Value Share by Region (2027-2032) Table 51. Global Pertuzumab Market Average Price (US$/Ton) by Region (2021-2026) Table 52. Global Pertuzumab Market Average Price (US$/Ton) by Region (2027-2032) Table 53. Global Pertuzumab Sales by Country: 2021 VS 2025 VS 2032 (Tons) Table 54. Global Pertuzumab Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Pertuzumab Sales by Country (2021-2026) & (Tons) Table 56. Global Pertuzumab Sales Market Share by Country (2021-2026) Table 57. Global Pertuzumab Sales by Country (2027-2032) & (Tons) Table 58. Global Pertuzumab Sales Market Share by Country (2027-2032) Table 59. Global Pertuzumab Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global Pertuzumab Sales Value Market Share by Country (2021-2026) Table 61. Global Pertuzumab Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global Pertuzumab Sales Value Market Share by Country (2027-2032) Table 63. Abnova Corporation Company Information Table 64. Abnova Corporation Business Overview Table 65. Abnova Corporation Pertuzumab Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 66. Abnova Corporation Pertuzumab Product Portfolio Table 67. Abnova Corporation Recent Development Table 68. Biocon Limited Company Information Table 69. Biocon Limited Business Overview Table 70. Biocon Limited Pertuzumab Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 71. Biocon Limited Pertuzumab Product Portfolio Table 72. Biocon Limited Recent Development Table 73. Bio-Techne Company Information Table 74. Bio-Techne Business Overview Table 75. Bio-Techne Pertuzumab Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 76. Bio-Techne Pertuzumab Product Portfolio Table 77. Bio-Techne Recent Development Table 78. Celltrion Company Information Table 79. Celltrion Business Overview Table 80. Celltrion Pertuzumab Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 81. Celltrion Pertuzumab Product Portfolio Table 82. Celltrion Recent Development Table 83. InvivoGen Company Information Table 84. InvivoGen Business Overview Table 85. InvivoGen Pertuzumab Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 86. InvivoGen Pertuzumab Product Portfolio Table 87. InvivoGen Recent Development Table 88. Pfizer Company Information Table 89. Pfizer Business Overview Table 90. Pfizer Pertuzumab Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 91. Pfizer Pertuzumab Product Portfolio Table 92. Pfizer Recent Development Table 93. Novartis AG Company Information Table 94. Novartis AG Business Overview Table 95. Novartis AG Pertuzumab Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 96. Novartis AG Pertuzumab Product Portfolio Table 97. Novartis AG Recent Development Table 98. Key Raw Materials Table 99. Raw Materials Key Suppliers Table 100. Pertuzumab Distributors List Table 101. Pertuzumab Customers List Table 102. Research Programs/Design for This Report Table 103. Authors List of This Report Table 104. Secondary Sources Table 105. Primary Sources List of Figures Figure 1. Pertuzumab Product Image Figure 2. Global Pertuzumab Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pertuzumab Sales Value (2021-2032) & (US$ Million) Figure 4. Global Pertuzumab Sales (2021-2032) & (Tons) Figure 5. Global Pertuzumab Sales Average Price (US$/Ton) & (2021-2032) Figure 6. Global Pertuzumab Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Human Source Image Figure 10. Animal Source Image Figure 11. Global Pertuzumab Sales Volume by Type (2021 VS 2025 VS 2032) & (Tons) Figure 12. Global Pertuzumab Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Pertuzumab Sales Volume Share by Type (2021-2032) Figure 14. Global Pertuzumab Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Pertuzumab Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Pertuzumab Sales Value Share by Type (2021-2032) Figure 17. Hospital Image Figure 18. Medical Center Image Figure 19. Global Pertuzumab Sales Volume by Application (2021 VS 2025 VS 2032) & (Tons) Figure 20. Global Pertuzumab Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Pertuzumab Sales Volume Share by Application (2021-2032) Figure 22. Global Pertuzumab Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Pertuzumab Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Pertuzumab Sales Value Share by Application (2021-2032) Figure 25. Global Pertuzumab Sales by Region: 2021 VS 2025 VS 2032 (Tons) Figure 26. Global Pertuzumab Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global Pertuzumab Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global Pertuzumab Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America Pertuzumab Sales Value (2021-2032) & (US$ Million) Figure 30. North America Pertuzumab Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe Pertuzumab Sales Value (2021-2032) & (US$ Million) Figure 32. Europe Pertuzumab Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific Pertuzumab Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific Pertuzumab Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America Pertuzumab Sales Value (2021-2032) & (US$ Million) Figure 36. South America Pertuzumab Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa Pertuzumab Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa Pertuzumab Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA Pertuzumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA Pertuzumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA Pertuzumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada Pertuzumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada Pertuzumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada Pertuzumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico Pertuzumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico Pertuzumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico Pertuzumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany Pertuzumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany Pertuzumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany Pertuzumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France Pertuzumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France Pertuzumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France Pertuzumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. Pertuzumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. Pertuzumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. Pertuzumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy Pertuzumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy Pertuzumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy Pertuzumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain Pertuzumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain Pertuzumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain Pertuzumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia Pertuzumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia Pertuzumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia Pertuzumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands Pertuzumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands Pertuzumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands Pertuzumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries Pertuzumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries Pertuzumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries Pertuzumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China Pertuzumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China Pertuzumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China Pertuzumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan Pertuzumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan Pertuzumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan Pertuzumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea Pertuzumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea Pertuzumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea Pertuzumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India Pertuzumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India Pertuzumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India Pertuzumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia Pertuzumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia Pertuzumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia Pertuzumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia Pertuzumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia Pertuzumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia Pertuzumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil Pertuzumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil Pertuzumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil Pertuzumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina Pertuzumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina Pertuzumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina Pertuzumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile Pertuzumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile Pertuzumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile Pertuzumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia Pertuzumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia Pertuzumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia Pertuzumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru Pertuzumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru Pertuzumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru Pertuzumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Pertuzumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia Pertuzumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Pertuzumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel Pertuzumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia Pertuzumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia Pertuzumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE Pertuzumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE Pertuzumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE Pertuzumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey Pertuzumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey Pertuzumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey Pertuzumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran Pertuzumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran Pertuzumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran Pertuzumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt Pertuzumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt Pertuzumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt Pertuzumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Pertuzumab Value Chain Figure 124. Manufacturing Cost Structure Figure 125. Pertuzumab Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • Human Source
  • Animal Source
Applications
  • Hospital
  • Medical Center
Companies covered
  • Abnova Corporation
  • Biocon Limited
  • Bio-Techne
  • Celltrion
  • InvivoGen
  • Pfizer
  • Novartis AG

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Pertuzumab Sales Value (2021-2032)
  4. 1.2.2 Global Pertuzumab Sales Volume (2021-2032)
  5. 1.2.3 Global Pertuzumab Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Pertuzumab Market Dynamics
  1. 2.1 Pertuzumab Industry Trends
  2. 2.2 Pertuzumab Industry Drivers
  3. 2.3 Pertuzumab Industry Opportunities and Challenges
  4. 2.4 Pertuzumab Industry Restraints
3 Pertuzumab Market by Company
  1. 3.1 Global Pertuzumab Company Revenue Ranking in 2025
  2. 3.2 Global Pertuzumab Revenue by Company (2021-2026)
  3. 3.3 Global Pertuzumab Sales Volume by Company (2021-2026)
  4. 3.4 Global Pertuzumab Average Price by Company (2021-2026)
  5. 3.5 Global Pertuzumab Company Ranking (2024-2026)
  6. 3.6 Global Pertuzumab Company Manufacturing Base and Headquarters
  7. 3.7 Global Pertuzumab Company Product Type and Application
  8. 3.8 Global Pertuzumab Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Pertuzumab Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Pertuzumab Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Pertuzumab Market by Type
  1. 4.1 Pertuzumab Type Introduction
  2. 4.1.1 Human Source
  3. 4.1.2 Animal Source
  4. 4.2 Global Pertuzumab Sales Volume by Type
  5. 4.2.1 Global Pertuzumab Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Pertuzumab Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Pertuzumab Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Pertuzumab Sales Value by Type
  9. 4.3.1 Global Pertuzumab Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Pertuzumab Sales Value by Type (2021-2032)
  11. 4.3.3 Global Pertuzumab Sales Value Share by Type (2021-2032)
5 Pertuzumab Market by Application
  1. 5.1 Pertuzumab Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Medical Center
  4. 5.2 Global Pertuzumab Sales Volume by Application
  5. 5.2.1 Global Pertuzumab Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Pertuzumab Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Pertuzumab Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Pertuzumab Sales Value by Application
  9. 5.3.1 Global Pertuzumab Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Pertuzumab Sales Value by Application (2021-2032)
  11. 5.3.3 Global Pertuzumab Sales Value Share by Application (2021-2032)
6 Pertuzumab Regional Sales and Value Analysis
  1. 6.1 Global Pertuzumab Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Pertuzumab Sales by Region (2021-2032)
  3. 6.2.1 Global Pertuzumab Sales by Region: 2021-2026
  4. 6.2.2 Global Pertuzumab Sales by Region (2027-2032)
  5. 6.3 Global Pertuzumab Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Pertuzumab Sales Value by Region (2021-2032)
  7. 6.4.1 Global Pertuzumab Sales Value by Region: 2021-2026
  8. 6.4.2 Global Pertuzumab Sales Value by Region (2027-2032)
  9. 6.5 Global Pertuzumab Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Pertuzumab Sales Value (2021-2032)
  12. 6.6.2 North America Pertuzumab Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Pertuzumab Sales Value (2021-2032)
  15. 6.7.2 Europe Pertuzumab Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Pertuzumab Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Pertuzumab Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Pertuzumab Sales Value (2021-2032)
  21. 6.9.2 South America Pertuzumab Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Pertuzumab Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Pertuzumab Sales Value Share by Country, 2025 VS 2032
7 Pertuzumab Country-level Sales and Value Analysis
  1. 7.1 Global Pertuzumab Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Pertuzumab Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Pertuzumab Sales by Country (2021-2032)
  4. 7.3.1 Global Pertuzumab Sales by Country (2021-2026)
  5. 7.3.2 Global Pertuzumab Sales by Country (2027-2032)
  6. 7.4 Global Pertuzumab Sales Value by Country (2021-2032)
  7. 7.4.1 Global Pertuzumab Sales Value by Country (2021-2026)
  8. 7.4.2 Global Pertuzumab Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Pertuzumab Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Pertuzumab Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Pertuzumab Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Pertuzumab Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Pertuzumab Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Pertuzumab Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Pertuzumab Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Pertuzumab Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Pertuzumab Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Pertuzumab Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Pertuzumab Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Pertuzumab Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Pertuzumab Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Pertuzumab Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Pertuzumab Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Pertuzumab Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Pertuzumab Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Pertuzumab Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Pertuzumab Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Pertuzumab Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Pertuzumab Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Pertuzumab Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Pertuzumab Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Pertuzumab Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Pertuzumab Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Pertuzumab Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Pertuzumab Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Pertuzumab Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Pertuzumab Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Pertuzumab Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Pertuzumab Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Pertuzumab Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Pertuzumab Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Pertuzumab Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Pertuzumab Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Pertuzumab Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Pertuzumab Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Pertuzumab Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Pertuzumab Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Pertuzumab Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Pertuzumab Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Pertuzumab Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Pertuzumab Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Pertuzumab Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Pertuzumab Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Pertuzumab Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Pertuzumab Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Pertuzumab Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Pertuzumab Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Pertuzumab Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Pertuzumab Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Pertuzumab Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Pertuzumab Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Pertuzumab Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Pertuzumab Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Pertuzumab Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Pertuzumab Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Pertuzumab Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Pertuzumab Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Pertuzumab Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Pertuzumab Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Pertuzumab Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Pertuzumab Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Pertuzumab Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Pertuzumab Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Pertuzumab Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Pertuzumab Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Pertuzumab Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Pertuzumab Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Pertuzumab Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Pertuzumab Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Pertuzumab Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Pertuzumab Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Pertuzumab Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Pertuzumab Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Pertuzumab Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Pertuzumab Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Pertuzumab Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Pertuzumab Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Pertuzumab Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Pertuzumab Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Pertuzumab Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Pertuzumab Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Pertuzumab Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Abnova Corporation
  2. 8.1.1 Abnova Corporation Company Information
  3. 8.1.2 Abnova Corporation Business Overview
  4. 8.1.3 Abnova Corporation Pertuzumab Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Abnova Corporation Pertuzumab Product Portfolio
  6. 8.1.5 Abnova Corporation Recent Developments
  7. 8.2 Biocon Limited
  8. 8.2.1 Biocon Limited Company Information
  9. 8.2.2 Biocon Limited Business Overview
  10. 8.2.3 Biocon Limited Pertuzumab Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Biocon Limited Pertuzumab Product Portfolio
  12. 8.2.5 Biocon Limited Recent Developments
  13. 8.3 Bio-Techne
  14. 8.3.1 Bio-Techne Company Information
  15. 8.3.2 Bio-Techne Business Overview
  16. 8.3.3 Bio-Techne Pertuzumab Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Bio-Techne Pertuzumab Product Portfolio
  18. 8.3.5 Bio-Techne Recent Developments
  19. 8.4 Celltrion
  20. 8.4.1 Celltrion Company Information
  21. 8.4.2 Celltrion Business Overview
  22. 8.4.3 Celltrion Pertuzumab Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Celltrion Pertuzumab Product Portfolio
  24. 8.4.5 Celltrion Recent Developments
  25. 8.5 InvivoGen
  26. 8.5.1 InvivoGen Company Information
  27. 8.5.2 InvivoGen Business Overview
  28. 8.5.3 InvivoGen Pertuzumab Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 InvivoGen Pertuzumab Product Portfolio
  30. 8.5.5 InvivoGen Recent Developments
  31. 8.6 Pfizer
  32. 8.6.1 Pfizer Company Information
  33. 8.6.2 Pfizer Business Overview
  34. 8.6.3 Pfizer Pertuzumab Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Pfizer Pertuzumab Product Portfolio
  36. 8.6.5 Pfizer Recent Developments
  37. 8.7 Novartis AG
  38. 8.7.1 Novartis AG Company Information
  39. 8.7.2 Novartis AG Business Overview
  40. 8.7.3 Novartis AG Pertuzumab Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Novartis AG Pertuzumab Product Portfolio
  42. 8.7.5 Novartis AG Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Pertuzumab Value Chain Analysis
  2. 9.1.1 Pertuzumab Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Pertuzumab Sales Mode & Process
  6. 9.2 Pertuzumab Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Pertuzumab Distributors
  9. 9.2.3 Pertuzumab Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst